Combining irinotecan liposomes and epirubicin for bladder cancer treatment after anthracyclines failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of a new treatment combining irinotecan liposomes administered intravenously and epirubicin given intravesically for patients with recurrent non-muscle invasive bladder urothelial carcinoma who have previously failed anthracycline therapy. The study will assess dose-limiting toxicities, the potential to reverse drug resistance, and the biological mechanisms involved in the treatment's effects. Participants will be divided into two arms to receive the treatment regimen and monitor their responses and side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* cTa-cT1N0M0 patients with non-muscle invasive urothelial carcinoma
* Tumor recurrence occurred after anthracyclines treatment
* Systemic chemotherapy had not been used
* Tumor is measurable according to New response evaluation criteria in solid tumours: Revised RECIST guideline
* ECOG (ZPS, 5-point scale) 0-1

Exclusion Criteria:

* Age less than 18 years
* Patients with severe cardiac, cerebral, hepatic, or renal disease
* Severely malnourished patients
* Patients with mental illness and those without insight and unable to express exactly
* Combined with malignant tumors of other organs
* Systemic infectious diseases

Where it's running

• The First Affiliated Hospital of Chongqing Medica University
  Chongqing, China Recruiting

Study contacts

• Study coordinator: Xin Gou, Professor
• Email: cymnk@163.com
• Phone: 0086+13650518875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining pembrolizumab with radiation therapy for bladder cancer treatment

  This study is testing if combining the immunotherapy drug pembrolizumab with radiation therapy can help people with non-muscle invasive bladder cancer do better than standard chemotherapy during treatment.

  Recruiting at 135 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 146 other locations · NCT06770582

• Combining Durvalumab and Monalizumab for Bladder Cancer Treatment

  This study is testing a combination of two drugs, durvalumab and monalizumab, to see if they can help people with certain types of bladder cancer that haven't responded to standard treatment.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · San Francisco, California and 4 other locations · NCT06503614

• Improving tumor detection before bladder cancer surgery

  This study is testing a new combination of tests to see if they can accurately find leftover tumors in bladder cancer patients before they have surgery.

  Recruiting at 2 sites Fox Chase Cancer Center · Omaha, Nebraska and 1 other locations · NCT06396533

• Tracking quality of life and relapses in bladder cancer patients after surgery

  This study is tracking how bladder cancer patients feel and whether their cancer comes back after surgery over the next 10 years.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT06167356

• MRI (VI-RADS) plus photodynamic-guided TURBT to avoid routine repeat bladder resections

  This study tests whether using a preoperative MRI VI-RADS score together with photodynamic-assisted TURBT can let people with non-muscle-invasive bladder cancer safely skip a routine second resection.

  Recruiting Phase 4 University of Roma La Sapienza · Rome, Lazio · NCT05962541

• Bicalutamide for non-muscle invasive bladder cancer

  This trial tests whether the anti-androgen drug bicalutamide changes EGFR protein expression in adult men with non-muscle invasive bladder cancer.

  Recruiting at 3 sites Phase 1 University of Wisconsin, Madison · Tucson, Arizona and 5 other locations · NCT05521698

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.